Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies
Jessie S. Kroonen, Ilona J. de Graaf, Sumit Kumar, et al.
Leukemia (2023) Vol. 37, Iss. 4, pp. 864-876
Open Access | Times Cited: 13

Showing 13 citing articles:

Concerted SUMO-targeted ubiquitin ligase activities of TOPORS and RNF4 are essential for stress management and cell proliferation
Julio C.Y. Liu, Leena Ackermann, Saskia Hoffmann, et al.
Nature Structural & Molecular Biology (2024) Vol. 31, Iss. 9, pp. 1355-1367
Open Access | Times Cited: 11
SUMOylation inhibition potentiates the glucocorticoid receptor to program growth arrest of acute lymphoblastic leukemia cells
Emma Valima, Vera Varis, Kseniia Bureiko, et al.
Oncogene (2025)
Open Access | Times Cited: 1
Insights into DNMT1 and programmed cell death in diseases
Lan Yan, Qi Geng, Zhiwen Cao, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115753-115753
Open Access | Times Cited: 19
SUMO and the DNA damage response
Jai S. Bhachoo, Alexander J. Garvin
Biochemical Society Transactions (2024) Vol. 52, Iss. 2, pp. 773-792
Open Access | Times Cited: 6
Enzymatic Processing of DNA–Protein Crosslinks
Maram M. Essawy, Colin Campbell
Genes (2024) Vol. 15, Iss. 1, pp. 85-85
Open Access | Times Cited: 5
SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacitidine in preclinical models of acute myeloid leukemia
Ludovic Gabellier, Marion de Toledo, Mehuli Chakraborty, et al.
Haematologica (2023)
Open Access | Times Cited: 11
Integrating Gene Demethylation and Immune Modulation: PD-1 Nanovesicles as a Dual-Action Therapy for NSCLC
Heng Zhang, Yuan Liang, Shiyang Deng, et al.
Materials Today Bio (2025), pp. 101851-101851
Open Access
Inhibition of TOPORS ubiquitin ligase augments the efficacy of DNA hypomethylating agents through DNMT1 stabilization
Satoshi Kaito, Kazumasa Aoyama, Motohiko Oshima, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
TOPORS E3 ligase mediates resistance to hypomethylating agent cytotoxicity in acute myeloid leukemia cells
Peter Truong, Sylvie Shen, Swapna Joshi, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Targeting epigenetic regulation and post-translational modification with 5-Aza-2’ deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy
Jessie S. Kroonen, Anne K. Wouters, Ilona J. de Graaf, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 9, pp. e008654-e008654
Open Access | Times Cited: 2
SENP1 knockdown potentiates the apoptosis, cell cycle arrest, and reduces cisplatin resistance of diffuse large B cell lymphoma cells via inducing ferroptosis
Jinfeng Dong, X. Zheng
Biochemistry and Cell Biology (2024) Vol. 102, Iss. 4, pp. 319-330
Closed Access | Times Cited: 1
Targeted inhibition of SUMOylation: treatment of tumors
Hongwei Zhao, Panpan Zhao, Chao Huang
Human Cell (2024)
Closed Access | Times Cited: 1
Concerted SUMO-targeted ubiquitin ligase activities of TOPORS and RNF4 are essential for stress management and cell proliferation
Julio C.Y. Liu, Leena Ackermann, Saskia Hoffmann, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Page 1

Scroll to top